CH484892A - Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds - Google Patents
Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compoundsInfo
- Publication number
- CH484892A CH484892A CH1718066A CH1718066A CH484892A CH 484892 A CH484892 A CH 484892A CH 1718066 A CH1718066 A CH 1718066A CH 1718066 A CH1718066 A CH 1718066A CH 484892 A CH484892 A CH 484892A
- Authority
- CH
- Switzerland
- Prior art keywords
- process according
- starting materials
- oxo
- oxido
- bisoxido
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000000034 method Methods 0.000 claims description 17
- 239000007858 starting material Substances 0.000 claims description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 5
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 claims description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 4
- 239000012285 osmium tetroxide Substances 0.000 claims description 4
- 150000003128 pregnanes Chemical class 0.000 claims description 4
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 claims description 4
- ALSXNTIVNJBNQE-ZWONNITHSA-N (8r,9r,10s,13r,14s,17s)-17-ethyl-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical class C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 ALSXNTIVNJBNQE-ZWONNITHSA-N 0.000 claims description 3
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- CPUKWYXYHPOQJH-RDQPJNLGSA-N (8r,9s,10s,13s,14s)-17-ethenyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)C=C)[C@@H]4[C@@H]3CCC21 CPUKWYXYHPOQJH-RDQPJNLGSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 229960002478 aldosterone Drugs 0.000 description 3
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OMIHGPLIXGGMJB-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2OC2=C1 OMIHGPLIXGGMJB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- -1 are produced Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 238000006567 deketalization reaction Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Description
Verfahren zur Herstellung von Il#,18-Oxido-18,21-dihydroxy-20-oxo-pregnanverbindungen <B>1</B> Die vorliegende Erfindung betrifft ein neues Ver- fahren zur Herstellung von 11#,18-Oxido-18,21-dihy- droxy-20-oxosteroide der Pregnanreihe oder der 19- Nor-pregnanreihe und ihrer tautomeren 18,20-Hemike- tale, unter anderern von Aldosteron und seinen Deri- vaten. Process for the production of 11#,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds <B>1</B> The present invention relates to a new process for the production of 11#,18-oxido-18 ,21-dihydroxy-20-oxosteroids of the pregnane series or the 19-norpregnane series and their tautomeric 18,20-hemiketals, including aldosterone and its derivatives.
Das er-findungsgemâl3e Verfahren ist dadurch ge- kennzeichnet, daG man die Doppelbindung in The process according to the invention is characterized in that the double bond is
Ausgangsstoffe für das neue Verfahren sind J20- Ilfl,18;18,20-Bisoxido-steroide der Pregnanreihe oder 19-Norpregnanreihe, wie sie z.B. durch Einwirkung einer Lewissâure auf eine in 21-Stellung unsubstituierte 11,18-Oxido-18-hydroxy-20-oxo-pregnanverbindung mit einer freien oder funktionell abgewandelten, reaktions- fâhigen 20-Oxogruppe in einem. inerten wasserfreien Medium erhalten werden kënnen. Die Ausgangsstoffe kônnen in den Ringen <B>A</B> und B gesâttigt sein, der 5a- oder 5fl-Reihe angehôren und <B>'</B> /oder Doppelbindungen enthalten, insbesondere in 1(2)- und/oder 4(5)- oder 5(6)-Stellung. Sie kônnen einen oder mehrere Substi- tuenten im Ringsystern aufweisen, wie beispielsweise freie, veresterte oder verâtherte Hydroxylgruppen, freie ketalisierte oder in Enolderivate umgewandelte Oxo- gruppen, niederc Alkyl- oder Alkylengruppen, wie Me- thyl-, Athyl- oder Methylengruppen, oder Halogen-, wie Fluor- oder Chloratome. The starting materials for the new process are J20-IIfl,18;18,20-bisoxido-steroids of the pregnane series or 19-norpregnane series, such as are produced, for example, by the action of a Lewis acid on an 11,18-oxido-18-hydroxy- 20-oxo-pregnane compound containing a free or functionally modified, reactive 20-oxo group in one. inert anhydrous medium can be obtained. The starting materials can be saturated in the rings <B>A</B> and B, belong to the 5a or 5fl series and contain <B>'</B> /or double bonds, especially in 1(2)- and/ or 4(5) or 5(6) position. They may have one or more substituents in the ring system, such as free, esterified or etherified hydroxyl groups, free oxo groups that are ketalized or converted into enol derivatives, lower alkyl or alkylene groups such as methyl, ethyl or methylene groups, or halogen -, such as fluorine or chlorine atoms.
Die verfahrensgemâl3e Dihydroxylierung der 20,21- Doppelbindung in den gekennzeichneten Ausgangsstof- fen wird in an sich bekannter Weise ausgefiihrt. Man lâl3t z. B. auf die Ausgangsstoffe Osmium- oder Ruthe- The process-related dihydroxylation of the 20,21-double bond in the indicated starting materials is carried out in a manner known per se. One lets e.g. B. to the starting materials osmium or ruthenium
einer -120-llf.,18;18,20-Bisoxido-pregnenverbindung di hydroxyliert. a dihydroxylated -120-11f.,18;18,20-bisoxido-pregnene compound.
Bei der verfahrensgemâBcn Dihydroxylierung der <B>ge-</B> nannten Ausgangsstoffe entstehen zunâchst die <B>18,20-</B> Hemiketale der llij',18-Oxido-18,21-dihydroxy-20-oxo steroide, die die tautomere Form der letzteren darstellen. Das Verfahren kann an folgendern Parti alformelsche ma illustriert werden: niumtetroxyd oder Mangandioxyd cinwirken, oder Was- serstoffperoxyd in Gegenwart von Osmiumtetroxyd, Wolframtrioxyd oder Vanadiumpentoxyd. Die Verfah- rensproduk-te liegen nach Isolierung aus der Reak-tions- lôsung vorherrschend in Form der <B>11</B> fl, <B>1</B> 8-Oxido- <B>18,2 1</B> - dihydroxy-20-oxo-pregnanverbindungen vor. Diese kôn- rien in bekannter Weise in 21-Stellung verestert werden, beispielsweise mittels organischer Carbonsâuren, vor- zugsweise solcher mit hôchstens 12 Kohlenstoffatomen, wie Ameisen-, Essig-, Trifluoressig-, Trimethylessig-, Propion, Bernstein-, Capron-, Hexahydrobenzoc-, Cy- clopentylpropion-, Benzoe- oder Furancarbonsâure, oder ihrer reaktionsfâhigen funktionellen Derivaten, z. B. der Halogenide oder Anhydride davon. During the process-related dihydroxylation of the <B>mentioned</B> starting materials, the <B>18,20-</B> hemiketals of the llij',18-oxido-18,21-dihydroxy-20-oxo steroids are formed first, representing the tautomeric form of the latter. The process can be illustrated using the following partial formula scheme: nium tetroxide or manganese dioxide act, or hydrogen peroxide in the presence of osmium tetroxide, tungsten trioxide or vanadium pentoxide. After isolation from the reaction solution, the products of the process are predominantly in the form of <B>11</B> fl, <B>1</B> 8-oxido- <B>18,2 1< /B> - dihydroxy-20-oxo-pregnane compounds. These can be esterified in a known manner in the 21-position, for example using organic carboxylic acids, preferably those with a maximum of 12 carbon atoms, such as formic, acetic, trifluoroacetic, trimethylacetic, propionic, succinic, caproic, hexahydrobenzoic -, cyclopentylpropionic, benzoic or furancarboxylic acid, or their reactive functional derivatives, e.g. B. the halides or anhydrides thereof.
Die fol enden Beispiele erlâutern die Erfindung ohne <B>9</B> e sie jedoch in irgendeiner Hinsicht einzuschrânk-en. Die Temperaturen sind in Celsiusgraden angegeben, The following examples illustrate the invention without restricting it in any way. Temperatures are given in degrees Celsius
<I>Beispiel <B>1</B></I> Eine Lésung von <B>3,7</B> mg J5,21-3,3-Àthylendioxy 11/3,18;18,20-bisoxido-pregnadien in <B>0,25</B> nil 1-mola- rem Pyridin in Benzol und<B>0,25</B> mt Äther wird bei <B>0-31</B> mit<B>2,8</B> bis<B>3,0</B> me Osmiumtetroxyd versetzt und 2 Stunden bei dieser Temperatur gerührt. Man ver dünnt dann das Reaktionsgemisch mit<B>0,75</B> ml Benzol- Äther <B>(1 : 1)</B> und schüttelt es mit<B>1</B> ml wässriger Na- triumascorbinatlösung (hergestellt durch Mischen glei cher Volumteile 0,5molarer 1-Ascorbinsäure- und 0,6- molarer Natriumhydrogencarbonatlösung,) <B>30</B> Minuten bei Raumtemperatur. Man extrahiert alsdann aus der unteren Phase das in Freiheit gesetzte Hydroxylierungs- produkt mit Benzol-Äther <B>(1 : 1),</B> wäscht die Extrakte mit wenig der obigen Natriumascorbinatlösung und Wasser, vereinigt sie, trocknet die Lösung mit Natrium sulfat und dampft sie ein. Der Rückstand stellt rohes ..11-3,3-Athylendioxy-1 li)l,18-oxido-18,21 -dihydroxy-20- oxo-pregnen dar. Er wird durch Abdampfen von <B>0,75</B> ml Benzol entwässert, hierauf in<B>0,1</B> ml Pyridin ge löst und die Lösung nach Zusetzen von 0,12 ml Acetan- hydrid <B>16</B> Stunden bei gewöhnlicher Temperatur stehen Crelassen. Man dampft das Reaktionsgernisch alsdann an der öl-Rotationspumpe ein, löst das erhaltene Acety- lierungsprodukt in<B>1</B> ml<B>67 %</B> iger Essigsäure und er wärmt es<B>1</B> Stunde in einer Stickstoffatrnosphäre auf <B>62-65'.</B> Die abgekühlte Lösung wird im Vakuum ein- enet und der Rückstand nach Zuaabe von 0,2n Am- ge <B>VD e</B> moniumhydrogencarbonat mit Metliylenchlorid-Äther <B>(1 :</B> 2) extrahiert. Die mit Wasser neutral gewaschenen Auszüge vereinigt man und dampft die mit Natriumsul fat getrocknete Lösung im Vakuum ein. Durch Um- kristallisieren des Rohproduktes aus wenig, Aceton- Äther erhält man<B>1,55</B> mc, #11-3,20-Dioxo- <B>11 1</B> 8-oxido- C, 18-hydroxy-2 <B>1</B> -acetoxy-prc,(,ynen (2<B>1</B> -0-Acetyl-aldoste- ron) vom F. 184-188,51. <I>Example <B>1</B></I> A solution of <B>3.7</B> mg of I5,21-3,3-ethylenedioxy 11/3,18;18,20-bisoxido -pregnadiene in <B>0.25</B> nil 1-molar pyridine in benzene and <B>0.25</B> mt ether is at <B>0-31</B> with <B >2.8</B> to <B>3.0</B> me of osmium tetroxide and stirred at this temperature for 2 hours. The reaction mixture is then diluted with <B>0.75</B> ml benzene ether <B>(1 : 1)</B> and shaken with <B>1</B> ml aqueous sodium ascorbinate solution (Prepared by mixing equal volumes of 0.5 molar 1-ascorbic acid and 0.6 molar sodium bicarbonate solution) <B>30</B> minutes at room temperature. The liberated hydroxylation product is then extracted from the lower phase with benzene ether <B>(1:1),</B>, the extracts are washed with a little of the above sodium ascorbinate solution and water, combined, and the solution is dried with sodium sulfate and evaporate it. The residue represents crude ..11-3,3-ethylenedioxy-1li)l,18-oxido-18,21-dihydroxy-20-oxo-pregnene. It is obtained by evaporating <B>0.75</B > ml of benzene dehydrated, then dissolved in <B>0.1</B> ml of pyridine and after adding 0.12 ml of acetic anhydride, the solution is allowed to stand for <B>16</B> hours at ordinary temperature. The reaction mixture is then evaporated using the oil rotary pump, the acetylation product obtained is dissolved in <B>1</B> ml<B>67%</B> acetic acid and it is heated <B>1</B > hour in a nitrogen atmosphere to <B>62-65'.</B> The cooled solution is concentrated in vacuo and the residue, after adding 0.2n Ammonium bicarbonate <B>VD e</B> Methylene chloride ether <B>(1 :</B> 2) extracted. The extracts, which have been washed neutral with water, are combined and the solution, which has been dried with sodium sulfate, is evaporated in vacuo. By recrystallizing the crude product from a little acetone ether, one obtains <B>1,55</B> mc, #11-3,20-dioxo- <B>11 1</B> 8-oxido- C, 18-hydroxy-2<B>1</B>-acetoxy-prc,(,ynen (2<B>1</B>-0-acetyl-aldosterone) from F. 184-188.51.
<I>Beispiel 2</I> Zu<B>3,7</B> mg A--,720-3,3-Äthylendioxy-lI#,18;18,20-bis- oxido-pregnadien in 0,20 ml Pyridin gibt man<B>0,10</B> ml einer wasserfreien, etwa Imolaren ätherischen Lösung von Wasserstoffperoxyd und<B>0,15</B> ml Äther, kühlt das Ganze auf<B>0-3'</B> ab und setzt dann<B>0,05</B> ml einer 0,02molaren Lösung von Osmiumtetroxyd in Pyridin zu. Der Ansatz wird<B>6</B> Stunden bei<B>0-3'</B> gerührt, hierauf mit Methylenchlorid-Äther <B>(1 :</B> 2) verdünnt und zuerst mit 0,25molarer wässeriger Natriumascorbinatlösung, dann mit Wasser ausceschüttelt. Die wässerigen Antleile <B>C</B> zieht man vor dem Verwerfen noch<B>je</B> zweimal mit fri schem Methylenchlorid-Äther <B>(1 :</B> 2) aus, vereinigt diese Extrakte mit der organischen Hauptphase, trocknet die Lösun(7 mit Natriumsulfat und dampft sie im Vakuum ein. Die anschliessende Acetylierung des Rückstandes und die Entketalisierung des erhaltenen Acetylisierungs- produkts erfolgt nach den im Beispiel<B>1</B> gemachten Anaaben und liefert nach präparativer papierchromato- graphischer Reinigung des Rohprodukts im System Formamid/Cyclohexan <B>-</B> Benzol<B>(1 :</B> 2) reines A'-3,20- Dioxo <B>- 1</B> lfl, <B>1</B> 8-oxido <B>- 18 -</B> hydroxy <B>-</B> 21<B>-</B> acetoxy <B>-</B> preg- nen (2<B>1</B> -0-Acetyl-aldosteron) vom F. 184-188,5'. <I>Example 2</I> To<B>3.7</B> mg A--,720-3,3-ethylenedioxy-lI#,18;18,20-bis-oxido-pregnadiene in 0, 20 ml of pyridine are added to<B>0.10</B> ml of an anhydrous, approximately 1 molar ethereal solution of hydrogen peroxide and<B>0.15</B> ml of ether, the whole thing is cooled to<B>0-3' </B> and then add<B>0.05</B> ml of a 0.02 molar solution of osmium tetroxide in pyridine. The batch is stirred for <B>6</B> hours at <B>0-3'</B>, then diluted with methylene chloride ether <B>(1 :</B> 2) and first with 0.25 molar aqueous sodium ascorbinate solution, then shaken out with water. The aqueous components <B>C</B> are extracted twice before discarding <B>each</B> with fresh methylene chloride ether <B>(1 :</B> 2), these extracts are combined of the organic main phase, the solution (7) is dried with sodium sulfate and evaporated in vacuo. The subsequent acetylation of the residue and the deketalization of the acetylation product obtained are carried out according to the methods described in example <B>1</B> and, after preparative Paper chromatographic purification of the raw product in the system formamide/cyclohexane <B>-</B> benzene<B>(1 :</B> 2) pure A'-3,20-dioxo <B>- 1</B> lfl, <B>1</B> 8-oxido <B>- 18 -</B> hydroxy <B>-</B> 21<B>-</B> acetoxy <B>-</B> pregnen (2<B>1</B> -0-acetyl-aldosterone) from F. 184-188.5'.
Claims (2)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1446167A CH512456A (en) | 1963-10-03 | 1963-10-03 | Bis-oxido steroids |
| CH1718066A CH484892A (en) | 1963-10-03 | 1963-10-03 | Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1217363A CH438293A (en) | 1963-10-03 | 1963-10-03 | Process for the preparation of bisoxide steroids of the pregnane series |
| CH1718066A CH484892A (en) | 1963-10-03 | 1963-10-03 | Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH484892A true CH484892A (en) | 1970-01-31 |
Family
ID=25709743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1446167A CH512456A (en) | 1963-10-03 | 1963-10-03 | Bis-oxido steroids |
| CH1718066A CH484892A (en) | 1963-10-03 | 1963-10-03 | Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1446167A CH512456A (en) | 1963-10-03 | 1963-10-03 | Bis-oxido steroids |
Country Status (1)
| Country | Link |
|---|---|
| CH (2) | CH512456A (en) |
-
1963
- 1963-10-03 CH CH1446167A patent/CH512456A/en not_active IP Right Cessation
- 1963-10-03 CH CH1718066A patent/CH484892A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH512456A (en) | 1971-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH484892A (en) | Process for preparing 11B,18-oxido-18,21-dihydroxy-20-oxo-pregnane compounds | |
| CH276556A (en) | Process for the preparation of pentaenes. | |
| DE969545C (en) | Process for the preparation of allopregnan-11, 20-dione-20-monoenol acylates | |
| DE2016704C3 (en) | A new, 14.15 ß-Oxidobufadienolide-LRhamnoside, active in the heart, and process for its preparation | |
| DE1643017C3 (en) | Process for the preparation of e-chloro-1,2alpha-methylene-delta nor 4,6-pregnadienes | |
| DE825686C (en) | Process for the conversion of í¸-20-cyanpregnenes with one or more nucleus-bound hydroxyl groups into 17 alpha-oxy-20-ketopregnanes | |
| DE1264441B (en) | Process for the production of 17alpha-AEthynyl-delta 5 (10-19-nor-androsten-17beta-ol-3-one and 17alpha-AEthynil-19-nor-testosterone and its esters | |
| DE1593697C (en) | Process for the production of 1 alpha alkoxy, 1 alpha alkenyloxy, 1 alpha alkynyl oxy or 1 alpha cycloalkyloxy, 5 alpha steroids | |
| DE962791C (en) | Process for the preparation of 21-bromoallopregnane derivatives | |
| AT233174B (en) | Process for the preparation of 3-keto-Δ4, 6-10 (α) -methyl steroids | |
| DE974201C (en) | Process for the reduction of compounds of the cyclopentanopolyhydrophenanthrene series | |
| AT209007B (en) | Process for the preparation of 9 α-halo-4-pregnen-16 α, 17 α, 21-triol-3, 11, 20-triones and their esters | |
| AT208525B (en) | Process for the production of aldosterone and its derivatives | |
| AT235477B (en) | Process for the preparation of new steroid compounds condensed with an isoxazole ring | |
| DE1169928B (en) | Process for the preparation of 21-bromo-5ª ‡ - or -5ª ‰ -pregnan-20-ones | |
| DE1142362B (en) | Process for the preparation of enol acylates of 16ª ‡ -alkyl-20-ketosteroids of the pregnan and allopregnan series | |
| DE1300941B (en) | Process for the preparation of delta 4-3-ketone android or pregnene compounds | |
| DE1193041B (en) | Process for making delta 7, delta 7.9, (11), delta 7.9, (11), 16, delta 7, delta 8 or delta 8.16 steroids | |
| DE1113453B (en) | Process for the production of substitution products of Reichsteins-Substance-S or their 21-acylates | |
| CH365066A (en) | Process for the preparation of 16a-methyl-pregnan-3a-ol-11,20-dione-3-acetate | |
| DE1443667B2 (en) | Process for the production of 11 beta, 18-oxldo-18,21-dihydroxy-20-oxopregnane compounds or their 21-esters as well as Delta high 20 -11 beta, 18,20-bisoxidopregnene intermediates | |
| CH520131A (en) | Bis-oxido steroids | |
| DE2424752A1 (en) | Steroid 17-spirolactones prepn. - by treating corresponding gamma-hydroxy-propionic acid dimethylamide cpds. with acidic cation exchangers | |
| DE1173467B (en) | Process for the preparation of 20-hydroxy-21-carboxylic acids of the pregnane series | |
| CH495969A (en) | Delta1 4-16alpha-methyl-steroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |